### Highlights of This Issue

#### SPECIAL FEATURES

- **CCR Translations**
  - **Metformin and Pancreatic Cancer: A Clue Requiring Investigation**
    - Michael Pollak
    - See article p. 2905

- **Molecular Pathways**
  - **Molecular Pathways: Vasculogenic Mimicry in Tumor Cells: Diagnostic and Therapeutic Implications**
    - Dawn A. Kirschmann, Elisabeth A. Seftor, Katharine M. Hardy, Richard E.R. Seftor, and Mary J.C. Hendrix

- **CCR Focus**
  - **Progress in Pediatric Cancer**
    - Susan E. Bates
  - **Genetically InFormed Therapies—A "GIFT" for Children with Cancer**
    - Carol J. Thiele and Susan L. Cohn
  - **Promising Therapeutic Targets in Neuroblastoma**
    - Katherine K. Matthay, Rani E. George, and Alice L. Yu
  - **Advances in the Genetics of High-Risk Childhood B-Progenitor Acute Lymphoblastic Leukemia and Juvenile Myelomonocytic Leukemia: Implications for Therapy**
    - Mignon L. Loh and Charles G. Mullighan
  - **Epigenetic Changes in Pediatric Solid Tumors: Promising New Targets**
    - Elizabeth R. Lawlor and Carol J. Thiele
  - **The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer**
    - Daniel W. Lee, David M. Barrett, Crystal Mackall, Rimas Orentas, and Stephan A. Grupp
  - **Using Germline Genomics to Individualize Pediatric Cancer Treatments**
    - Navin Pinto, Susan L. Cohn, and M. Eileen Dolan

### HUMAN CANCER BIOLOGY

- **Suppression of Skeletal Muscle Turnover in Cancer Cachexia: Evidence from the Transcriptome in Sequential Human Muscle Biopsies**
- **MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma**

### Perspective

- **Disrupting the Networks of Cancer**
  - Daniel F. Camacho and Kenneth J. Pienta

- **Pharmacogenomics in Early-Phase Oncology Clinical Trials: Is There a Sweet Spot in Phase II?**
  - Peter H. O'Donnell and Walter M. Stadler
Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients
Daniela Speisky, Aurélie Duces, Pascal Hammel, Vinciane Rebourc, Alain Sauvanet, Stéphane Richard, Pierre Bedossa, Michel Vidaud, Arnaud Murat, Patricia Niccoli, Jean-Yves Scouazer, Philippe Ruszniewski, and Anne Couvelard for the GTE Group (Groupe d’Etude des Tumeurs Endocrines)

CANCER THERAPY: PRECLINICAL

Lyn Kinase Mediates Cell Motility and Tumor Growth in EGFRvIII-Expressing Head and Neck Cancer
Sarah E. Wheeler, Elena M. Morariu, Joseph S. Bednash, Charlton G. Otte, Raja R. Seethala, Simion I. Chiosea, and Jennifer R. Grandis

IMAGING, DIAGNOSIS, PROGNOSIS

Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study
Harri Sihto, Tom Böhlind, Heli Kavola, Virve Koljonen, Marno Salmin, Sirpa Jalkanen, and Heikki Joensuu

Global Methylation Profiling for Risk Prediction of Prostate Cancer
Saswati Mahapatra, Eric W. Klee, Charles Y.F. Young, Zhifu Sun, Rafael E. Jimenez, George G. Klee, Donald J. Tindall, and Krishna Vanaja Donkena

Correlation of ERG Expression and DNA Methylation Biomarkers with Adverse Clinicopathologic Features of Prostate Cancer
Ken Kron, Liyuan Liu, Dominique Trudel, Vaijayanti Pethe, John Trachtenberg, Neil Fleschner, Bharati Bapat, and Theodorus van der Kwast

CANCER THERAPY: CLINICAL

Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
Navid Sadeghi, James L. Abbuzzese, Sai-Ching J. Yeung, Manal Hassan, and Donghui Li
See commentary p. 2723

Pharmacokinetics and Repolarization Effects of Intravenous and Transdermal Granisetron
Jay W. Mason, Daniel S. Selness, Thomas E. Moon, Bridget O’Mahony, Peter Donachie, and Julian Howell

Survival of 1,181 Patients in a Phase I Clinic: The M.D. Anderson Clinical Center for Targeted Therapy Experience
Jennifer Wheleer, Apostolia M. Tsimberidou, David Hong, Aung Naing, Gerald Falchook, Sarina Piha-Paul, Siqing Fu, Stacy Moulder, Betzy Stephen, Sijin Wen, and Razelle Kurzrock

Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy

Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response
Yann Godet, Elizabeth Fabre, Magalie Dosset, Michele Lamuraglia, Emeline Levinnois, Patrice Ravel, Nadine Benhamoua, Aurèle Cazes, Françoise Le Pimpesc-Barthes, Beatrice Gaugler, Pierre Langlade-Demoyen, Xavier Pivot, Philippe Saas, Bernard Maille, Eric Tartour, Christophe Borg, and Olivier Adotiev

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432
PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

2964  Gender Influences the Class III and V β-Tubulin Ability to Predict Poor Outcome in Colorectal Cancer
        Marisa Mariani, Gian Franco Zannoni, Stefano Sioletic, Steven Sieber, Candice Martino, Enrica Martinelli, Claudio Coco, Giovanni Scambia, Shohreh Shahabi, and Cristiano Ferlini

2976  An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial
        Florence de Fraipont, Guénèlle Levallet, Christian Creveuil, Emmanuel Bergot, Michèle Beau-Faller, Mounia Mounawar, Nicolas Richard, Martine Antoine, Isabelle Rouquette, Marie-Christine Favrot, Didier Debieuvre, Denis Braun, Virginie Westeel, Elisabeth Quoix, Elisabeth Brambilla, Pierre Hainaut, Denis Moro-Sibilot, Franck Morin, Bernard Milleron, and Gérard Zalcman on behalf of the Intergroupe Francophone de Cancérologie Thoracique (IFCT)

ABOUT THE COVER

Methylation of the tumor suppressor gene Ras association domain family IA (RASSF1A) is an independent adverse prognostic factor in patients with early-stage non–small cell lung carcinoma treated in the phase III trial on perioperative chemotherapy, IFCT-0002. The cover image is a photomicrograph showing RASSF1A protein distribution in immortalized interphasic bronchial epithelial cells, HBEC3, using confocal microscopy. RASSF1A is stained in red (Alexa-fluor red-labeled secondary antibody). Nuclei are shown in light purple (DAPI). For details, see the article by de Fraipont and colleagues on page 2976 of this issue.